The CPHI & PMEC India 2023 edition, the platform where international and domestic pharma experts meet to do business, network and shape the future of the pharmaceutical industry in India and South East Asia, will soon be back in Delhi. Steriline Asia will be participating for the first time, welcoming visitors at its stand 10.D23, subevent P-MEC, from 28th to 30th November.
The pharma industry represents a great opportunity for all the stakeholders in the Asian pharmaceutical supply chain: the Indian market is growing at an annual rate of 15%, twice the growth rate of the world market . To make the most of this opportunity, Steriline Asia, born last June from the union of Steriline and INCOME, is being led by Mr Chiranjeevi Kondapaka as Chief Executive Officer and benefits from Mr Vishesh Parekh’s business mentorship. “The close-knit team, coming from INCOME, benefits from strong knowledge and expertise,” states Mr Chiranjeevi Kondapaka. “Joining Steriline means the team will soon be boosted by improved tools and processes for faster response. We are going to expand it by hiring more experts, with the goal of continuing to provide the excellent full service support that the team has provided to the national market for more than thirty years.”
An installed base of 100+ filling lines in India alone, comprising 800+ machines, is a testimony to the fact that the industry has really appreciated Steriline technology combined with INCOME service as a local agent, transforming India into the biggest and most important market for Steriline in just a few decades.
Steriline develops, manufactures and supplies a comprehensive range of solutions, including both mechanical and robotic applications for aseptic processing. These applications are compatible with vials, ampoules, cartridges and syringes and can handle toxic or non-toxic products in both liquid and powder form. “Mechanical and robotic technologies are different but complementary,” states Filippo Parini, Sales Area Manager at Steriline. “The latter address all the issues related to small batch production, such as flexibility, reduced format changes, minimisation of product loss. The former are indicated when higher speed and big batch production are required. Steriline, with its complete product portfolio, can satisfy the requirements of the Indian market in terms of fill & finish equipment, ranging from personalised medicines and CDMO productions to the production of generics. Thanks to its brand-new subsidiary in India, Steriline is now more efficient, effective and closer to local customers and partners than ever before.”
The Indian Pharmaceutical Industry is today at the cusp of a transformation process and Steriline Asia is pledging to continue to be at the forefront, offering solutions which are value-for-money propositions specifically engineered for Indian operations.
“In this way, we will be even more responsive to the ever changing and evolving needs of our customers,” concludes Mr Chiranjeevi Kondapaka.
